ArticleCureus2025
Correlation of Liver Enzymes and Blood Parameters With Histopathological Severity in Benign and Malignant Liver Lesions.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLiver lesions, whether benign or malignant, often present with nonspecific clinical features, making early diagnosis and prognostication challenging. Histopathological evaluation remains the gold standard, but serum biomarkers could offer non-invasive alternatives for assessing disease severity.
objectivesThis study aimed to evaluate the role of liver enzymes and hematological parameters in differentiating benign from malignant liver lesions and to correlate these markers with histopathological severity. METHODOLOGY: A prospective observational study was conducted at Ayub Medical College, Abbottabad, Pakistan, from January to December 2024, involving 120 patients with radiologically confirmed liver lesions. Blood samples were analyzed for alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), total and direct bilirubin, hemoglobin, leukocyte count, platelet count, and erythrocyte sedimentation rate (ESR) using standard laboratory protocols. Histopathological grading of malignant lesions was performed on hematoxylin and eosin (H&E)-stained sections. Independent t-tests and one-way analysis of variance (ANOVA) were applied to assess group differences, and Pearson's correlation analysis was used to examine associations with tumor grade.
resultsAmong 120 patients, 72 (60%) had malignant and 48 (40%) had benign liver lesions. Malignant lesions demonstrated significantly elevated ALT, AST, ALP, and bilirubin levels, along with lower hemoglobin and higher leukocyte counts and ESR (p < 0.001 for all). These parameters also showed significant progressive changes across low-, intermediate-, and high-grade malignancies. Strong positive correlations were found between histopathological grade and ALT (r = 0.61), AST (r = 0.68), ALP (r = 0.59), and ESR (r = 0.71), while hemoglobin showed a strong negative correlation (r = -0.65). Platelet count did not significantly differ between groups or correlate with severity.
conclusionRoutine liver enzymes and hematological markers demonstrate significant diagnostic and prognostic value in evaluating liver lesions. Their integration into clinical workflows may enhance early detection, especially in resource-limited settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.